相关临床试验
23
22 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
1982
进行中（未招募）
22
95.7%
招募中
1
4.3%
- Sacituzumab govetecan, an FDA-approved breast cancer drug, demonstrated significant activity in treatment-resistant uterine cancer, shrinking tumors by 30% or more in 28% of patients in a Phase II trial. - The antibody-drug conjugate targets Trop-2 protein on cancer cells, delivering chemotherapy directly to tumor sites while sparing healthy tissue from widespread toxicity. - Over 70% of the 50 enrolled patients experienced some degree of tumor shrinkage, representing one of the most effective third-line treatments for uterine cancer to date. - The promising results have prompted initiation of a Phase III trial comparing the drug to standard chemotherapy in a larger patient population.
- Gilead Sciences acquired Sprint Bioscience's preclinical TREX1 cancer program for $14 million upfront plus up to $400 million in milestone payments. - TREX1 is a first-in-class immuno-oncology target that helps tumors evade immune detection by degrading cytosolic DNA that would normally trigger immune responses. - Preclinical data showed TREX1 inhibition activates interferon pathways, slows tumor growth, and increases immune cell infiltration, potentially enhancing responses to multiple cancer therapies. - The acquisition strengthens Gilead's oncology portfolio as the company seeks new options following setbacks with its existing cancer drug Trodelvy.
- Protara Therapeutics has appointed William Conkling as Chief Commercial Officer, bringing over two decades of experience in developing and commercializing cancer and rare disease therapeutics. - Conkling previously led commercial organizations at Rafael Holdings, Immunomedics, and Novartis, including the successful launch of Trodelvy for triple negative breast cancer and Kymriah CAR-T therapy. - The appointment positions Protara for potential transition to a commercial-stage organization as it advances TARA-002 for bladder cancer and lymphatic malformations through Phase 2 trials.
• Cargo Therapeutics has suspended development of its CD22-directed cell therapy for lymphoma due to serious adverse events in Phase II trials, leading to a 50% workforce reduction. • The company maintains $368 million in cash reserves as of end-2024 and plans to continue work on other pipeline programs while evaluating strategic options. • The situation has ignited industry-wide debate about whether biotech companies with negative enterprise value should return cash to shareholders or persist with development programs.
• Gilead Sciences has executed over $27 billion worth of strategic oncology deals in 2020, marking its most aggressive push yet to establish leadership in cancer treatment. • Under new leadership, including CEO Daniel O'Day and CFO Andrew Dickinson, Gilead has acquired Immunomedics for $21 billion and made significant investments in multiple biotech companies focused on immuno-oncology. • The company aims to balance its traditional antiviral portfolio with a strong oncology presence, highlighted by the acquisition of Trodelvy, while maintaining approximately $11 billion for future strategic investments.
- AstraZeneca has entered a $6 billion collaboration with Daiichi Sankyo to develop DS-1062, a novel antibody-drug conjugate targeting TROP2, a protein highly expressed in multiple cancer types. - The partnership includes an upfront payment of $1 billion from AstraZeneca, with potential additional payments of up to $5 billion based on regulatory and sales milestones. - The companies will jointly develop and commercialize DS-1062 globally for multiple TROP2-expressing tumors, particularly focusing on lung and breast cancers, building on their previous successful collaboration with Enhertu.
